Statistics
The warfarin-naive cohort from the ARISTOTLE study was considered the closest data set to the patients being recruited into this study. The predicted incidence of stroke, systemic embolism, and major bleeding within 30 days after randomization was approximately 0.75%. To adequately power for a noninferiority trial, approximately 48,000 participants would be needed, a number in excess of feasibility. The figure of 1,500 patients was considered clinically meaningful and achievable. Nonvalvular atrial fibrillation (NVAF) is a modern epidemic affecting 1 in 4 adults aged 60 years and older. 1 Electrical or pharmacological cardioversion, or both together are standard practice for restoring sinus rhythm in selected patients with persistent atrial fibrillation (AF). 2 The risk of periprocedural thromboembolism may exceed 5% when anticoagulation is inadequate. 3, 4 Therapeutic anticoagulation with a vitamin K antagonist (VKA) reduces the risk to b1%. [5] [6] [7] Current practice guidelines recommend anticoagulation for at least 3 weeks before and at least 4 weeks after cardioversion for patients with AF lasting N48 hours or when the duration is uncertain. 2, 8, 9 Secondary post hoc analyses of the RE-LY trial, 7 the ARISTOTLE trial, 10 and the ROCKET-AF trial 11 suggest that the non-VKA oral anticoagulants (NOACs) may be a reasonable alternative to heparin and warfarin for patients with NVAF undergoing cardioversion and that event rates are very low (Table I ). The major limitation of these post hoc analyses, however, is the prolonged period of anticoagulation preceding the cardioversion. The need for more immediate cardioversion frequently arises in patients presenting with newly identified AF. The X-VeRT trial 12 was the first prospective trial of a NOAC in the setting of cardioversion and found rivaroxaban, an oral factor Xa inhibitor, comparable to VKA in patients with NVAF undergoing cardioversion within 5 days or after 3 weeks and up to a maximum of 8 weeks of anticoagulation, once again with very low event rates (0.5% and 0.6% for efficacy and safety for rivaroxaban and 1.0% and 0.8% for usual therapy, both not significantly different). No studies have specifically evaluated a NOAC in a population of patients who are anticoagulation naïve and who are undergoing cardioversion. EMANATE will uniquely address cardioversion in this population.
Clinical context

Apixaban
Apixaban is an orally active, reversible, direct inhibitor of human coagulation factor Xa developed jointly by Bristol-Myers Squibb (BMS) and Pfizer as an antithrombotic agent, now licensed globally for the prevention of stroke and systemic embolization in patient with NVAF and for treatment and prevention of venous and thromboembolic disease. 13 
Objectives
The goal of this study is to assess clinical outcomes in patients randomized to apixaban against conventional anticoagulant care (parenteral heparin and/or a VKA) in patients with recently detected AF considered for cardioversion. T he protocol encourages an image-guided approach (transesophageal echocardiography [TEE] or computed tomography [CT]) or anticoagulation for a minimum of 3 weeks before cardioversion. 2, 8 To avoid confounding by prior treatment, the study focuses on patients who are anticoagulation naïve, excluding patients receiving any anticoagulant for N48 hours during the index episode of AF. Another aim of the study is to define predictors of a successful outcome at 30 days after cardioversion.
Design
This is a randomized, active-controlled, open-label study of approximately 1,500 patients randomized 1:1 to apixaban or usual care (parenteral heparin and/or oral anticoagulation with VKAs (goal international normalized ratio [INR] 2.0-3.0, excluding other NOACs; Figure 1 ). Anticoagulation is administered from randomization until 30 days after cardioversion. If cardioversion is not performed, anticoagulation will be administered for a maximum of 90 days. Clinical data including cardioversion details, efficacy and safety outcomes, length of in-hospital stay, and information regarding image guidance are collected. The apixaban dose is 5 mg BID, with a dose reduction to 2.5 mg BID if at least 2 of the following exist: age N80 years, weight b60 kg, or serum creatinine N1.5 mg/dL. Five doses of apixaban will be administered before cardioversion to achieve steady-state blood levels. If an immediate cardioversion is planned, a single 10 mg dose (or 5 mg if the dose is down-titrated) is administered at least 2 hours before cardioversion to more rapidly bring exposure up to steady state. Investigators will use their local label for dose adjustment guidance for participants with renal impairment. (See Fig. 2) .
Participants randomized to apixaban will transition from their preexisting anticoagulant (oral and/or parenteral) of b48 hours as follows. For participants receiving a VKA, apixaban is started when the INR is below 2.0. For all NOACs, discontinue the drug and begin apixaban at the next scheduled dose but no earlier than 12 hours after the previous oral anticoagulant administration. For low-molecular-weight heparin, apixaban should be started at the time of the next scheduled dose and no earlier than 12 hours after the previous parenteral anticoagulation administration. For intravenous (IV) infusion of unfractionated heparin (UFH), apixaban may be started between 0 and 2 hours after IV UFH has been stopped.
For participants randomized to usual therapy, stop NOAC and start warfarin immediately, and start heparin at Participant flow.
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the time of the next dose of the novel agent and continue until the INR is above 2. In general, patients will be managed according to the local clinician's usual practice and in a manner consistent with the design of the study.
Statistical considerations
There was no precedent for evaluating anticoagulation-naïve patients in the setting of cardioversion. The warfarin-naive cohort from the ARISTOTLE study 14 was considered the closest data set to the patients being recruited into this study. The incidence of stroke and systemic embolism within 30 days after randomization was 0.3% (1 stroke or systemic embolism on apixaban and 3 events on usual care). The incidence of major bleeding was 0.45% (2 events on apixaban and 5 events on usual care). To adequately power for noninferiority, 480 end points would be needed (similar to ARISTOTLE 15 ). In this study, follow-up is limited to 30 days after cardioversion or 90 days postrandomization. An estimated event rate of approximately 1% would require 48,000 participants, a number far in excess of practicality. The figure of 1,500 patients was considered clinically meaningful and achievable. Kaplan-Meier curves of the time to first adjudicated stroke or systemic embolism, first major bleeding event, and composite of first major bleed and clinically relevant nonmajor bleed as well as all-cause death will be generated.
Executive Committee
The Executive Committee (EC) comprises 5 academic experts, 4 sponsor representatives (nonvoting), and a biostatistician. The EC takes sole responsibility for the study design, trial management, data analysis, and writing of the manuscript. The EC reviews recommendations from the Data Monitoring Committee (DMC) and oversees the presentation and publication of the results. The EC is aided by a clinical research organization and by designated national leaders in both cardiology and emergency medicine in the participating countries. This trial is sponsored by BMS and Pfizer. The authors acknowledge the editorial assistance of Ms. Paulette Trent.
Data Monitoring Committee
An independent DMC is responsible for monitoring the safety of participants in the study and recommending alterations of the study to the EC and the sponsor. The sponsor forwards decisions, which may include aggregate analyses of end point events and safety data that are not end points, to regulatory authorities as appropriate.
Study procedures
Screening
The investigator or designee at each participating clinical site obtains written informed consent from each participant, as well as contact and demographic information, relevant medical history, and CHA 2 DS 2 VASc score, and evaluates clinical laboratory results ( Figure 2 ). The patient must meet inclusion and exclusion criteria, including electrocardiographic confirmation of heart rhythm (Tables II and III) . These tables additionally compare the inclusion and exclusion criteria from the first completed trial of rivaroxaban (X-VeRT) 16 and a second ongoing trial of edoxaban (ENSURE-AF) 17 that, like EMANATE, prospectively evaluate novel anticoagulants in the setting of cardioversion.
Randomization
Randomization uses a centralized interactive voice-response system. Study medication is dispensed in accordance with local policies and procedures, with accounting recorded on case report forms. Patients can be randomized and cardioverted on the same day, combining visits 1 and 2.
Cardioversion
The following details are recorded for each cardioversion attempted: time and date attempted; whether pharmacological, electrical, both pharmacological and electrical, or spontaneous; local investigator interpretation of image guidance; type of image guidance; number, date, and time of cardioversion attempts; rhythm status after cardioversion; and adverse events (AEs).
Compliance
Compliance with apixaban is based on pill counts at the time of cardioversion and at the end of the study. For patients randomized to usual care, compliance is assessed by INR monitoring.
Image guidance
In the event TEE or CT imaging identifies atrial thrombus, cardioversion is deferred for at least 3 weeks. Assigned anticoagulation continues, and imaging is repeated to confirm resolution of thrombus before cardioversion. We encourage investigators to continue assigned medication in patients identified with thrombus and repeat imaging studies after 3 weeks.
Management of bleeding
Anticoagulation is interrupted in the event of clinically significant bleeding and managed according to local practice, which may include such measures as surgical hemostasis, volume repletion, transfusion of blood products, and for patients in the conventional therapy arm, administration of protamine and supplemental vitamin K fresh-frozen plasma, as deemed appropriate by the treating physician. An antidote to apixaban is in development but is not yet approved. 18 
Treatment transitions
At the end of the study or upon early withdrawal from the study, the patient's subsequent management and treatment are conducted by the treating physician according to usual practice. When an alternative anticoagulation strategy is necessary, the protocol recommends the transition procedures contained in the apixaban package insert. 13 
Participant withdrawal
Participants may withdraw from the study at any time upon request, at the discretion of the investigator or sponsor for safety or behavioral reasons, or because of the inability of the participant to comply with the required schedule of visits or procedures. Participants withdrawn from the study are subsequently managed according to conventional practice. Every effort will be made to ensure follow-up for outcomes relevant to the trial objectives.
Assessment
Clinical outcomes
Clinical outcomes are assessed by local investigators to determine whether a protocol-specified outcome had occurred. Events are recorded and reviewed by independent adjudicators blinded to treatment allocation. The clinical outcomes are the occurrence of acute stroke, systemic embolism, all-cause death, major bleeding, and clinically relevant nonmajor bleeding.
Acute stroke
Stroke is defined as a focal neurological deficit of sudden onset, lasting at least 24 hours, not due to a readily identifiable nonvascular cause. Strokes are classified as primary ischemic, hemorrhagic, infarction with hemorrhagic conversion, or of unknown type if no imaging is available in accordance with definitions established by the American College of Cardiology. 19 A diagnosis of primary hemorrhagic stroke requires documentation by imaging of hemorrhage in the cerebral parenchyma or in the subdural or subarachnoid space or evidence of hemorrhage obtained by lumbar puncture neurosurgery or identified at autopsy. Nonhemorrhagic stroke is a focal neurological deficit resulting from thrombosis or embolism evident at 24 hours. Infarction with hemorrhagic conversion requires absence of hemorrhage on initial scan but evidence of hemorrhage on subsequent scan. Stroke of unknown type is designated when brain imaging is not available. Participants with AF after a cardiac surgical procedure (including catheter ablation) will be allowed into the study, providing that they meet all the other inclusion criteria and the time from the surgery to randomization is no b30 d. The investigator will be responsible for assessment of risks relevant to the cardioversion procedure in such participants.
ECG, Electrocardiogram; IRB, Institutional Review Board; IEC, Institutional Ethics Committee. Previous randomization in this study Participants receiving chronic cyclosporine therapy Inability to comply with the study procedures Participants with active liver disease or persistent (confirmed by repeat assessments at least a week apart) elevation of liver enzymes/bilirubin: alanine transaminase or aspartate transaminase ≥3× ULN; TBL ≥2× ULN (however, participants whose elevated TBL is due to known Gilbert syndrome may be included in the study) Participants with renal failure (end stage renal disease, calculated CrCl b15 mL/min) Participants with hemoglobin b10 g/dL or platelet count b100000 cells/mcL or white blood cell count b3000 cells/mcL Participants with preplanned invasive procedures (other than routine endoscopy) or surgeries in which bleeding is anticipated during the study period Participants who received any investigational drug or device within 30 d before randomization or plan to receive such investigational therapy during the study period Women of childbearing potential without proper contraceptive measures and women who are pregnant or breastfeeding Note: childbearing potential without proper contraceptive measures (ie, a method of contraception with a failure rate b1% during the course of the study [including the observational period]. These methods of contraception according to the note for guidance on nonclinical safety studies for the conduct of human trials for pharmaceuticals [CPMP/ICH/286/95, modification] include consistent and correct use of hormone containing implants and injectables, combined oral contraceptives, hormone containing intrauterine devices, surgical sterilization, sexual abstinence, and vasectomy for the male partner) Participants with the following diagnoses or situations: -Active cancer undergoing chemotherapy, radiation, or major surgery within the next 3 m; -Significant active concurrent medical illness or infection; life expectancy N6 m; Participants who are unlikely to comply with the protocol (eg, uncooperative attitude, inability to (continued on next page)
Extracranial systemic embolism
Systemic embolism is defined by a clinical presentation consistent with acute loss of blood supply to an anatomical site supplied by a single artery, supported by evidence from angiography, surgical specimens, autopsy, or other objective testing.
Major bleeding
Clinically overt bleeding is defined as visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging that detects the presence of blood (eg, ultrasound, CT, or magnetic resonance). The definition of major bleeding adapted from the International Society on Thrombosis and Hemostasis 20 requires clinically overt bleeding accompanied by 1 or more of the following: a decrease in hemoglobin of N2 g/dL; transfusion of N2 units of packed red blood cells; bleeding that occurs in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal; or bleeding that is fatal.
Clinically relevant nonmajor bleeding
The definition of clinically overt bleeding in the EMANATE protocol is adapted from the International Society on Thrombosis and Hemostasis guidelines. 21 Clinically relevant nonmajor bleeding is an overt bleed that compromises hemodynamics, leads to hospitalization, produces subcutaneous hematoma N25 cm 2 , or 100 cm 2 if traumatic, intramuscular hematoma documented by ultrasonography, and epistaxis lasting N5 minutes or repetitive (ie, 2 or more episodes of bleeding within 24 hours), or leads to intervention (eg, packing or electrocoagulation); gingival bleeding occurring spontaneously (ie, unrelated to eating or tooth brushing) or lasting N5 minutes; spontaneous macroscopic hematuria lasting N24 hours after instrumentation (eg, catheter placement or surgery); macroscopic gastrointestinal hemorrhage, including at N1 episode of melena or hematemesis, if clinically apparent, and hemoptysis outside the context of pulmonary embolism; or any other bleeding considered to have clinical consequences such as medical intervention, unscheduled contact (visit or telephone call) with a physician, temporary interruption of study drug, or associated with pain or impaired activities of daily life.
Length of hospital stay
The date and time of each hospital admission and discharge will be recorded.
Adverse events
An AE is defined as any untoward medical occurrence or worsening of a preexisting medical condition in a participant administered an anticoagulant during the course of the study.
Serious adverse events. Serious adverse events are untoward medical occurrence that are life threatening or fatal, require inpatient hospitalization or prolong an existing hospitalization, result in persistent or significant disability or incapacity, congenital anomaly or birth defect, require intervention to prevent permanent impairment or damage, or based on medical judgment, are important medical events that place a participant in jeopardy and require medical or surgical intervention to prevent 1 of the aforementioned outcomes.
Discussion
The novelty of this trial is the exclusive enrollment of anticoagulant-naïve patients with recently detected AF with a focus on enrolling those patients amenable to early cardioversion. Also unique, if an immediate cardioversion is planned, is the administration of a loading dose of 10 mg (or 5 mg if the dose is down-titrated) of apixaban at least 2 hours before cardioversion. This is done to more rapidly achieve a steady state of anticoagulation. For this reason, potential participants are being actively identified in hospital emergency departments. Image-guided cardioversion with TEEs or CT scans is of special interest. Thus, the Assessment of Cardioversion Use in Transesophageal Echocardiography study, 6 a multicenter, randomized trial comparing a TEE-guided strategy of abbreviated therapeutic anticoagulation with IV UFH started 24 hours before cardioversion against conventional warfarin (INR 2.0-3.0) for at least 3 weeks before cardioversion, provided important background information. The investigators enrolled 1,222 patients with AF of N2 days duration and found no significant difference between the 2 strategies in the rate of thromboembolic events for an 8-week period. The rate of hemorrhagic events was lower in the TEE-guided group (18 events [2.9%] vs 33 events [5.5%], P = .03). The TEE group had a shorter time to cardioversion (mean ± SD, 3.0 ± 5.6 vs 30.6 ± 10.6 days). The authors concluded that the strategy of TEE-guided treatment was a safe and effective alternative to the conventional treatment strategy. 6 Additional data relevant to cardioversion derive from a post hoc subgroup analysis of the ARISTOTLE trial, in which 540 participants underwent 743 cardioversions and were followed up for 30 days after cardioversion. No stroke or systemic embolic events occurred in patients randomized to apixaban or warfarin. One major bleeding event and 2 deaths were observed in each group. 10 All participants undergoing cardioversion in that trial had been chronically anticoagulated before cardioversion, so there was no information on the safety of apixaban in participants newly presenting with AF or in those patients naïve to anticoagulation in whom early cardioversion is indicated. The EMANATE trial is designed to fill this important information gap.
The first and largest post hoc analysis of cardioversion was in the RE-LY trial, which found similarly low event rates in groups treated with warfarin or either of 2 doses of dabigatran, 150 mg BID or 110 mg BID. 7 The analysis provided grounds for optimism regarding the potential use of a NOAC in this setting (Table I) . Subsequently, secondary analysis of the ROCKET-AF trial described a similar experience with rivaroxaban in a smaller number of patients insofar as event rates were low (Table I) . 11 The ENGAGE-AF trial of edoxaban also included patients undergoing cardioversion, but the data are not currently available.
The only prospective trial to specifically address cardioversion was the X-VeRT trial, which tested rivaroxaban against usual therapy.
12 Site investigators decided whether to randomize participants to early (1-5 days after randomization) or delayed cardioversion (between 21 and 56 days after randomization). Event rates were low in both arms, with a nonsignificant trend favoring rivaroxaban. Another ongoing prospective trial, ENSURE-AF, is evaluating edoxaban against usual care in patients with AF undergoing cardioversion. 17 
Limitations
EMANATE is an ongoing open-label trial. There is precedent for conducting open-label anticoagulation trials with blinded adjudication. 12, 17, [22] [23] [24] The outcomes of these completed trials are very similar to those of completed double-blind trials, 10, 11, 24, 25 thus, confirming the validity of this type of trial design.
We also describe the difficulty of conducting a statistically valid noninferiority trial in the setting of cardioversion due to the very large sample size required because of low event rates reported in all the recent cardioversion trials evaluating novel agents. This limitation was recognized in the design of the comparable X-VeRT and ENSURE-AF trials. We did consider a cohort study using apixaban alone with comparison to historic controls; however, the unique feature of EMANATE is the anticoagulation-naïve population for which a historical control group would not be available. There is evidence that apixaban is being used in the setting of cardioversion in certain sites without direct evidence to support this approach. We do believe that this study fills an important data gap and that the results of this study should bear importantly upon future clinical practice.
